Technical Analysis for INBX - Inhibrx, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 34.58 | -0.09% | -0.03 |
Earnings due: May 6
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | -0.09% | |
NR7 | Range Contraction | -0.09% | |
Lower Bollinger Band Walk | Weakness | -0.09% | |
Stochastic Reached Oversold | Weakness | -0.09% | |
BB Squeeze + Lower Band Touch | Range Contraction | -0.09% | |
Gapped Up | Strength | -0.09% | |
Lower Bollinger Band Touch | Weakness | -0.09% | |
Oversold Stochastic | Weakness | -0.09% | |
Bollinger Band Squeeze | Range Contraction | -0.09% | |
Lower Bollinger Band Walk | Weakness | -0.09% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | 20 minutes ago |
Reversed from Up | about 18 hours ago |
Possible NR7 | about 20 hours ago |
Possible Inside Day | about 20 hours ago |
Gap Up Closed | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/06/2024
Inhibrx, Inc. Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 39.79 |
52 Week Low | 14.305 |
Average Volume | 495,059 |
200-Day Moving Average | 26.73 |
50-Day Moving Average | 36.05 |
20-Day Moving Average | 34.90 |
10-Day Moving Average | 34.82 |
Average True Range | 0.50 |
RSI (14) | 39.39 |
ADX | 19.27 |
+DI | 12.42 |
-DI | 18.13 |
Chandelier Exit (Long, 3 ATRs) | 33.92 |
Chandelier Exit (Short, 3 ATRs) | 36.00 |
Upper Bollinger Bands | 35.21 |
Lower Bollinger Band | 34.59 |
Percent B (%b) | 0.03 |
BandWidth | 1.77 |
MACD Line | -0.27 |
MACD Signal Line | -0.30 |
MACD Histogram | 0.0317 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 35.00 | ||||
Resistance 3 (R3) | 35.03 | 34.94 | 34.94 | ||
Resistance 2 (R2) | 34.94 | 34.84 | 34.92 | 34.91 | |
Resistance 1 (R1) | 34.77 | 34.78 | 34.73 | 34.74 | 34.89 |
Pivot Point | 34.68 | 34.68 | 34.65 | 34.66 | 34.68 |
Support 1 (S1) | 34.51 | 34.58 | 34.47 | 34.48 | 34.33 |
Support 2 (S2) | 34.42 | 34.52 | 34.40 | 34.31 | |
Support 3 (S3) | 34.25 | 34.42 | 34.29 | ||
Support 4 (S4) | 34.22 |